Obsession with Soliris should not detract from Alexion pipeline, says analyst

28 March 2019

A broker’s report on Alexion Pharmaceuticals (Nasdaq: ALXN) has found that the popular perception of the US pharma as the 'Soliris (eculizumab) company' does not do justice to its pipeline.

Alexion is seeking to grow beyond the runaway success of the blood disorder therapy, which is used to treat paroxysmal nocturnal hemoglobinuria (PNH) and atypical hemolytic uremic syndrome and brought in more than $3.5 billion in sales for the firm last year.

With Soliris’ exclusivity due to end in 2020 in Europe and 2026 in the USA and competitors looming, there has been a perception that the company’s future hinges on the success of Ultomiris (ravulizumab-cwvz), causing an overhang on its stock.

This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Try before you buy

Free

7 day trial access

Take a Free Trial

All the news that moves the needle in pharma and biotech
Exclusive features, podcasts, interviews, data analyses and commentary from our global network of life sciences reporters.
Receive The Pharma Letter daily news bulletin, free forever.

Become a subscriber

£820

Or £77 per month

Subscribe Now

Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
Daily roundup of key events in pharma and biotech.
Monthly in-depth briefings on Boardroom appointments and M&A news.
Choose from a cost-effective annual package or a flexible monthly subscription

The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK